Related Experiment Video
Updated: Jan 4, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer
Neele Schumacher1, Stefan Rose-John1
1Biochemical Institute, University of Kiel, 24118 Kiel, Germany.
Abstract:
All ligands of the epidermal growth factor receptor (EGF-R) are transmembrane proteins, which need to be proteolytically cleaved in order to be systemically active. The major protease responsible for this cleavage is the membrane metalloprotease ADAM17, which also has been implicated in cleavage of TNFα and interleukin-6 (IL-6) receptor. It has been recently shown that in the absence of ADAM17, the main protease for EGF-R ligand processing, colon cancer formation is largely abrogated. Intriguingly, colon cancer formation depends on EGF-R activity on myeloid cells rather than on intestinal epithelial cells. A major activity of EGF-R on myeloid cells is the stimulation of IL-6 synthesis. Subsequently, IL-6 together with the ADAM17 shed soluble IL-6 receptor acts on intestinal epithelial cells via IL-6 trans-signaling to induce colon cancer formation, which can be blocked by the inhibitor of IL-6 trans-signaling, sgp130Fc. Blockade of IL-6 trans-signaling therefore offers a new therapeutic window downstream of the EGF-R for the treatment of colon cancer and possibly of other EGF-R related neoplastic diseases.
Insights
Blocking IL-6 trans-signaling effectively inhibits colon cancer by targeting epidermal growth factor receptor (EGF-R) activity on myeloid cells. This approach offers a new therapeutic strategy for EGF-R-related cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Epidermal growth factor receptor (EGF-R) ligands are transmembrane proteins requiring proteolytic cleavage for systemic activity.
- ADAM17 is a key metalloprotease involved in cleaving EGF-R ligands, TNFα, and IL-6 receptor.
- EGF-R activity on myeloid cells, not epithelial cells, drives colon cancer formation.
Purpose of the Study:
- To investigate the role of ADAM17 and IL-6 trans-signaling in EGF-R-mediated colon cancer.
- To explore therapeutic strategies targeting downstream pathways of EGF-R in colon cancer.
Main Methods:
- Analysis of colon cancer formation in the absence of ADAM17.
- Investigating the role of IL-6 synthesis and IL-6 trans-signaling.
- Evaluating the efficacy of sgp130Fc, an IL-6 trans-signaling inhibitor.
Main Results:
- Colon cancer formation is significantly reduced in the absence of ADAM17.
- EGF-R signaling on myeloid cells stimulates IL-6 synthesis.
- IL-6 trans-signaling, involving shed IL-6 receptor, drives colon cancer and can be blocked by sgp130Fc.
Conclusions:
- ADAM17-mediated cleavage and subsequent IL-6 trans-signaling are crucial for colon cancer development.
- Inhibiting IL-6 trans-signaling presents a viable therapeutic strategy for colon cancer.
- This pathway blockade may also be effective for other EGF-R-related neoplastic diseases.
Related Concept Videos
The JAK-STAT Signaling Pathway
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Autocrine Signaling
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
TGF - β Signaling Pathway
Psychoneuroimmunology: Diabetes and Cancer

